Kill Criteria

Kill criteria emerged from the discipline of stage-gate project management developed by Robert G. Cooper in the 1980s. Cooper's research at McMaster University revealed that most organizations lacked formal mechanisms for stopping failing projects, resulting in massive resource waste. His Stage-Gate process introduced decision checkpoints where projects had to meet predefined criteria to advance, with explicit provisions for termination. This framework revolutionized product development at companies like Procter & Gamble, 3M, and Emerson Electric.

The psychological foundation for kill criteria lies in well-documented cognitive biases. Escalation of commitment, also known as the sunk-cost fallacy, causes decision-makers to continue investing in failing initiatives because of resources already spent rather than future prospects. Nobel laureate Daniel Kahneman's research on loss aversion shows that people experience losses roughly twice as intensely as equivalent gains, making project termination psychologically painful even when it is economically rational. Kill criteria counteract these biases by shifting the termination decision from a subjective judgment call to an objective assessment against predetermined standards.

In practice, effective kill criteria span multiple dimensions. Financial kill criteria might include failing to achieve a minimum return on investment by a specified date, exceeding budget by more than a defined percentage, or falling below revenue run-rate thresholds. Strategic kill criteria address shifts in market conditions, competitive dynamics, or organizational priorities that render the initiative's original rationale obsolete. Technical kill criteria specify performance benchmarks, quality standards, or feasibility milestones that the project must achieve. Intel famously applied kill criteria when it exited the memory chip business in 1985, a decision driven by predefined profitability thresholds that memory products could no longer meet, freeing resources for the microprocessor business that would define the company's future.

The pharmaceutical industry provides perhaps the most rigorous application of kill criteria. Drug development pipelines use clearly defined go/no-go criteria at each clinical trial phase. Pfizer, Merck, and other major pharmaceutical companies have formal kill criteria for efficacy endpoints, safety profiles, and market size projections at Phase I, II, and III gates. This discipline is essential in an industry where fewer than 12% of drug candidates that enter clinical trials ultimately receive regulatory approval, and the cost of bringing a drug to market exceeds $2 billion on average.

Implementing kill criteria requires establishing them at the outset of a project, before teams develop emotional attachment. The criteria must be specific, measurable, and agreed upon by all stakeholders. Critically, organizations must also create a culture where killing a project is treated as a responsible strategic decision rather than a failure. Google's practice of publicly celebrating project shutdowns and reassigning teams to higher-potential initiatives exemplifies this approach. Without cultural support, even well-defined kill criteria will be ignored, rationalized away, or quietly revised to keep struggling projects alive.